p44/p42-MAP kinase expression in papillary thyroid carcinomas

Michelle C. Specht, Catherine B. Barden, Thomas J. Fahey

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background. Recent studies suggest that mitogen-activated protein (MAP) kinase contributes to the growth and tumorigenesis of human epithelial cancers. Furthermore, blockade of this pathway may inhibit the growth of epithelial cancers. To determine whether MAP kinase is activated in human papillary thyroid carcinomas (PTCs), we analyzed the presence of native MAP kinase (MAPK) and activated phosphorylated MAP kinase (pMAPK) in papillary thyroid cancers and thyroid carcinoma cell lines. Methods. Protein from paired specimens of 10 patients with PTC was analyzed by immunoblot for MAPK and pMAPK. In addition, MAPK protein expression and cell growth were analyzed in 3 thyroid tumor cell lines treated with a mitogen extracellular kinase inhibitor, U0126. Results. All 10 PTCs had equal expression of MAPK in the tumors and adjacent normal tissue. Six of the 10 tumors demonstrated increased expression of the pMAPK in the tumor specimen compared to the adjacent normal tissue. Interestingly, 3 of 4 patients without differential expression had multifocal PTC. The pMAPK was expressed constitutively in 3 thyroid cancer cell lines. The MAPK inhibitor treatment decreased pMAPK expression and decreased serum-induced growth in all 3 cell lines. Conclusions. MAP kinase activation is common in PTCs and may offer a potential target for growth inhibition of PTCs.

Original languageEnglish (US)
Pages (from-to)936-940
Number of pages5
JournalSurgery
Volume130
Issue number6
DOIs
StatePublished - 2001

Fingerprint

Mitogen-Activated Protein Kinase 1
Mitogen-Activated Protein Kinases
Phosphotransferases
Thyroid Neoplasms
Growth
Neoplasms
Cell Line
Mitogen-Activated Protein Kinase Kinases
Papillary Thyroid cancer
Tumor Cell Line
Mitogens
Protein Kinases
Thyroid Gland
Carcinogenesis
Serum
Proteins

ASJC Scopus subject areas

  • Surgery

Cite this

p44/p42-MAP kinase expression in papillary thyroid carcinomas. / Specht, Michelle C.; Barden, Catherine B.; Fahey, Thomas J.

In: Surgery, Vol. 130, No. 6, 2001, p. 936-940.

Research output: Contribution to journalArticle

Specht, Michelle C. ; Barden, Catherine B. ; Fahey, Thomas J. / p44/p42-MAP kinase expression in papillary thyroid carcinomas. In: Surgery. 2001 ; Vol. 130, No. 6. pp. 936-940.
@article{d2d8b8d409004e4da7dd1925e39313d4,
title = "p44/p42-MAP kinase expression in papillary thyroid carcinomas",
abstract = "Background. Recent studies suggest that mitogen-activated protein (MAP) kinase contributes to the growth and tumorigenesis of human epithelial cancers. Furthermore, blockade of this pathway may inhibit the growth of epithelial cancers. To determine whether MAP kinase is activated in human papillary thyroid carcinomas (PTCs), we analyzed the presence of native MAP kinase (MAPK) and activated phosphorylated MAP kinase (pMAPK) in papillary thyroid cancers and thyroid carcinoma cell lines. Methods. Protein from paired specimens of 10 patients with PTC was analyzed by immunoblot for MAPK and pMAPK. In addition, MAPK protein expression and cell growth were analyzed in 3 thyroid tumor cell lines treated with a mitogen extracellular kinase inhibitor, U0126. Results. All 10 PTCs had equal expression of MAPK in the tumors and adjacent normal tissue. Six of the 10 tumors demonstrated increased expression of the pMAPK in the tumor specimen compared to the adjacent normal tissue. Interestingly, 3 of 4 patients without differential expression had multifocal PTC. The pMAPK was expressed constitutively in 3 thyroid cancer cell lines. The MAPK inhibitor treatment decreased pMAPK expression and decreased serum-induced growth in all 3 cell lines. Conclusions. MAP kinase activation is common in PTCs and may offer a potential target for growth inhibition of PTCs.",
author = "Specht, {Michelle C.} and Barden, {Catherine B.} and Fahey, {Thomas J.}",
year = "2001",
doi = "10.1067/msy.2001.118381a",
language = "English (US)",
volume = "130",
pages = "936--940",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - p44/p42-MAP kinase expression in papillary thyroid carcinomas

AU - Specht, Michelle C.

AU - Barden, Catherine B.

AU - Fahey, Thomas J.

PY - 2001

Y1 - 2001

N2 - Background. Recent studies suggest that mitogen-activated protein (MAP) kinase contributes to the growth and tumorigenesis of human epithelial cancers. Furthermore, blockade of this pathway may inhibit the growth of epithelial cancers. To determine whether MAP kinase is activated in human papillary thyroid carcinomas (PTCs), we analyzed the presence of native MAP kinase (MAPK) and activated phosphorylated MAP kinase (pMAPK) in papillary thyroid cancers and thyroid carcinoma cell lines. Methods. Protein from paired specimens of 10 patients with PTC was analyzed by immunoblot for MAPK and pMAPK. In addition, MAPK protein expression and cell growth were analyzed in 3 thyroid tumor cell lines treated with a mitogen extracellular kinase inhibitor, U0126. Results. All 10 PTCs had equal expression of MAPK in the tumors and adjacent normal tissue. Six of the 10 tumors demonstrated increased expression of the pMAPK in the tumor specimen compared to the adjacent normal tissue. Interestingly, 3 of 4 patients without differential expression had multifocal PTC. The pMAPK was expressed constitutively in 3 thyroid cancer cell lines. The MAPK inhibitor treatment decreased pMAPK expression and decreased serum-induced growth in all 3 cell lines. Conclusions. MAP kinase activation is common in PTCs and may offer a potential target for growth inhibition of PTCs.

AB - Background. Recent studies suggest that mitogen-activated protein (MAP) kinase contributes to the growth and tumorigenesis of human epithelial cancers. Furthermore, blockade of this pathway may inhibit the growth of epithelial cancers. To determine whether MAP kinase is activated in human papillary thyroid carcinomas (PTCs), we analyzed the presence of native MAP kinase (MAPK) and activated phosphorylated MAP kinase (pMAPK) in papillary thyroid cancers and thyroid carcinoma cell lines. Methods. Protein from paired specimens of 10 patients with PTC was analyzed by immunoblot for MAPK and pMAPK. In addition, MAPK protein expression and cell growth were analyzed in 3 thyroid tumor cell lines treated with a mitogen extracellular kinase inhibitor, U0126. Results. All 10 PTCs had equal expression of MAPK in the tumors and adjacent normal tissue. Six of the 10 tumors demonstrated increased expression of the pMAPK in the tumor specimen compared to the adjacent normal tissue. Interestingly, 3 of 4 patients without differential expression had multifocal PTC. The pMAPK was expressed constitutively in 3 thyroid cancer cell lines. The MAPK inhibitor treatment decreased pMAPK expression and decreased serum-induced growth in all 3 cell lines. Conclusions. MAP kinase activation is common in PTCs and may offer a potential target for growth inhibition of PTCs.

UR - http://www.scopus.com/inward/record.url?scp=0035659969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035659969&partnerID=8YFLogxK

U2 - 10.1067/msy.2001.118381a

DO - 10.1067/msy.2001.118381a

M3 - Article

C2 - 11742320

AN - SCOPUS:0035659969

VL - 130

SP - 936

EP - 940

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 6

ER -